Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Insight Genetics is dedicated to improving the lives of cancer patients around the world through advanced diagnostics for precision cancer care. They are a molecular diagnostics company that is working to further precision cancer care at times of diagnosis, treatment and therapeutic resistance. They specialize in the discovery, development and commercialization of companion diagnostics. In addition, Insight Genetics' CLIA-certified Insight Molecular Labs provides unique, high-value cancer testing services to oncologists and pharmaceutical companies. A key priority in cancer care today is increasing the effectiveness of cancer treatment through a new generation of therapies that are targeted to specific genetic biomarkers. Fast, accurate and comprehensive tests – called companion diagnostics – are required to make these targeted therapies possible. These tests help clinicians pinpoint which targeted therapies may or may not work for a particular patient. They operate at the intersection of drug development and patient care. With a high level of scientific expertise and assay development capabilities, as well as CLIA and GLP testing services, Insight Genetics spans the spectrum of discovery, testing, and commercialization of companion diagnostics. Insight is dedicated to developing new technologies and diagnostic tests that will become cutting-edge clinical products.

Part of Sihuan Pharmaceutical Holdings Group Ltd., Shandong Xuanzhu Pharmaceutical Technology Co., Ltd. is a company headquartered in China. The firm engages in the research, development and sale of pharmaceutical products.

Xuanzhu Biopharmaceutical Co., Ltd. engages in the research and development of chemical and biological drugs. Its products include small molecular chemical drugs, monoclonal antibodies, bispecific antibodies, and antibody conjugated drugs. The company was founded in 2002 and is headquartered in Shijiazhuang, China.

Cell Signaling Technology, Inc. (CST) is a privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study the cell signaling pathways that impact human health. CST maintains an in-house research program, particularly in the area of cancer research, and has published scientific papers in many peer-reviewed journals.

Guangzhou Zaiji Medical Technology Co. Ltd. is a Chinese company that manufactures medical devices.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Hefei Zhongkepu Ruisheng Biomedical Technology Co., Ltd., established on 2015-07-16, Business scope includes research on biomedical engineering technology,to develop,transfer,consultation service,Biomedical Experimental Technology Services,Experimental technology consulting service and transfer;Biological experiment reagent,Development of Consumables for Biological Experiments,Sales;Drug and medical information consultation service;Self-operated and agent import and export business of various commodities and technologies(Except for those restricted or prohibited by the state);clinical body fluid,blood test;Clinical tissue and cell biology assays,Molecular genetics professional testing;Medical testing consultation;Medical Information Consultation;data collection;Big Data Services and Applications;Research and development of biomedical technology and software technology,technical consulting,Technical Services,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Nanjing Hongyun Biotechnology Co., Ltd. is a company headquartered in Nanjing, China, that operates as a biotechnology company. It was founded in 2018 by Xin Huang and Cai Hong Yun. Xin Huang has been the CEO since that date.

Wuxi Aorui Dongyuan Biotechnology Co., Ltd., established on 2010-10-13, Business scope includes biological genetic products,biomedicine,Biomaterials Research,to develop,technology transfer,technical consulting;Pharmaceutical Intermediates,Comprehensive agent for experiment,Manufacture and sales of medical devices(Items requiring a permit,Operate with a valid license);Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export);Biological product,biologics,Manufacture and sale of specific immunoglobulin products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Nanjing Leizheng Pharmaceutical Technology Co., Ltd., established on 2015-09-17, The scope of business includes R&D and technical consultation of pharmaceuticals and their intermediates,Technical Services,technology transfer;Chemicals(Does not contain hazardous chemicals)Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Roche Sequencing Solutions, Inc. engages in providing personalized healthcare by creating diagnostics and treatments tailored to individual genetic and disease profiles. The firm's solutions include NGS Oncology Assays, sample collection, nucleic acid extraction and library preparation. The company is headquartered in Pleasanton, CA.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

It was founded in 2001 by Alexey Repik. In 2017, 10% of JSC R-Pharm’s shares were acquired by Japanese Corporation Mitsui & Co., Ltd. The mission of R-Pharm is to increase the accessibility of the most modern medicines for patients in Russia and all over the world. The staff consists of more than 3,000 highly qualified professionals. The group of companies operates throughout the Russian Federation, CIS member states, USA, Germany, Japan and other countries. There are more than 70 branches and representative offices. R-Pharm’s headquarters are located in Moscow. R-Pharm specializes in research and development, manufacturing of high-tech medicines, as well as the distribution of laboratory supplies and medical equipment. Various Russian leading medical institutions and organizations are among the clients of the group. R-Pharm Group owns several state-of-the-art manufacturing sites in Russia and abroad: high-tech packaging site in Kostroma region, a plant for production of finished dosage forms and biotechnological APS in Yaroslavl, pilot manufacturing site in Moscow, a plant for production of solid dosage forms in Illertissen (Germany). A modern research and APS manufacturing site in Rostov and Russian-Azerbaijani pharmaceutical plant in Baku are under construction. In 2018 R-Pharm and Rosatom agreed to create a joint manufacturing plant in Moscow. R-Pharm has its own research and development facilities, which allows it to conduct various activities in partnership with the leading Russian and foreign academic institutes. R-pharm signed numerous agreements on product manufacturing localization, technology transfer and licensing with the biggest pharmaceutical companies from all over the world. The portfolio of the group includes medicines for various therapeutic areas : oncological, hematologic, cardiological, immunological, antibacterial, antiviral, including HIV therapy, pharmaceuticals used during and after organ transplantation, treatment of multiple sclerosis, hemophilia, as well as muscle relaxants, contrast agents and anesthetics.

Suzhou Yasheng Pharmaceutical Co., Ltd., established on 2016-06-01, The business scope includes the production of targeted drugs,R & D and sales,and provide technical services,technical consulting;Self-operated above-mentioned goods,Import and export business of technology and services,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of;investment management.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Non-residential real estate leases(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)